Movetis

Contact
movetis.com
+3214404390

Movetis NV

Veedijk 58 (1004)
2300 Turnhout
Belgium
+3214404390
movetis.com
Contact
Profile News
Contact

About Movetis

MOVETIS is developing their portfolio of eight products and two discovery platforms which are concentrated on important areas of unmet medical need, including severe, chronic constipation, ascites, pediatric reflux, diabetic gastroparesis and severe forms of dyspepsia.

Read more about Movetis
Facts about Movetis
  • Focus : Manufacturer
  • Industry : Pharma

News about Movetis

Movetis

05-Oct-2010 | business & finance

Movetis wins two out of three categories at the PharmaVentures European Deals 2010 Awards

Movetis NV announced that it has won the European Financing Deal of the Year and the European M&A Deal of the Year at the PharmaVentures European Deals ...

Read news
Movetis

28-Sep-2010 | research and development

Movetis starts phase III clinical trial with prucalopride in male patients with chronic constipation

Movetis NV announced that it has started a phase III clinical trial with prucalopride in male patients with chronic constipation. Positive results from ...

Read news
Movetis

06-Aug-2010 | research and development

Movetis receives authorisation to market Resolor in Switzerland

Switzerland is the 31st country where Resolor is authorised on the market

Read news
Movetis

21-May-2010 | research and development

Movetis starts Phase III clinical trial with prucalopride in patients with opioid-induced constipation (OIC)

New trial marks first step in Movetis’ label expansion strategy for Resolor

Read news
Movetis

26-Oct-2009 | research and development

Movetis obtains EU authorisation for the commercialisation of Resolor (prucalopride)

Movetis announced that it has obtained approval from the European Commission for the commercialisation of its lead product Resolor (prucalopride – a 1mg ...

Read news
Movetis

07-Jul-2008 | research and development

Movetis' second most advanced product progresses to Phase IIb trial following positive results in cirrhotic ascites

Movetis NV, a European specialist pharmaceutical company, announced that M0002 is progressing to phase IIb following positive results of a phase IIa ...

Read news
Movetis

04-Feb-2008 | research and development

New class of highly selective 5-HT4 receptor agonists provides the next generation of GI treatments

A scientific review of the different pharmacological profiles of 5-HT4 receptor agonists published in Neurogastroenterology and Motility concludes that, ...

Read news
Movetis

11-Jun-2007 | research and development

Movetis Announces Start of a Phase IIa trial for M0002 in Ascites

Movetis NV, a Belgian biopharmaceutical company that specializes in developing compounds for gastrointestinal disorders, announced the start of a Phase-IIa ...

Read news
Show more news about Movetis

Here you will find Movetis NV